Page last updated: 2024-12-07

benzyloxyamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzyloxyamine is a versatile reagent used in organic synthesis, particularly for the formation of oximes, amides, and other nitrogen-containing compounds. It is a white crystalline solid with a melting point of 54-56 °C. The compound is typically synthesized by the reduction of benzoyl chloride with lithium aluminum hydride followed by reaction with hydroxylamine. Benzyloxyamine is known to exhibit inhibitory effects on certain enzymes, including acetylcholinesterase. Its ability to react with carbonyl compounds, forming stable oximes, has led to its use in the development of various pharmaceuticals and agrochemicals. Researchers study benzyloxyamine for its potential applications in drug discovery, catalysis, and materials science.'

benzyloxyamine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102313
CHEMBL ID443652
SCHEMBL ID7948
MeSH IDM0067515

Synonyms (39)

Synonym
622-33-3
BB 0257240
hydroxylamine, o-(phenylmethyl)-
hydroxylamine, o-benzyl-
o-benzylhydroxylamine
NCGC00166093-01
benzyloxyamine
STK400321
bdbm50146579
AKOS000311516
CHEMBL443652 ,
benzyl-o-hydroxylamine
o-benzyl-hydroxylamine
o-(phenylmethyl)hydroxylamine
SCHEMBL7948
(phenylmethoxy)amine
o-benzylhydroxyamine
o-benzyloxylamine
nh2och2ph
phenylmethoxyamine
o-benzyl hydroxylamine
bnonh2
o-benzyl hydroxyamine
STR08364
snr 1635
(benzyloxy)amine
DTXSID8073213
CS-W008955
o-benzylhydroxylamine, aldrichcpr
mfcd00221709
SY018100
FT-0699866
Q27464086
AMY24029
BBL040921
o-(phenylmethyl)hydroxylamine; o-benzylhydroxylamine; o-benzyloxyamine; snr 1635; alpha-(aminooxy)toluene
benzyloxylamine
N10409
o-(phenylmethyl)hydroxylamine; o-benzylhydroxylamine; o-benzyloxyamine; snr 1635; -(aminooxy)toluene
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Indoleamine 2,3-dioxygenase 1Homo sapiens (human)IC50 (µMol)5.40500.05373.075710.0000AID1266390; AID1276958
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
regulation of activated T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell tolerance inductionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of chronic inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of type 2 immune responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
inflammatory responseIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
female pregnancyIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan catabolic process to kynurenineIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
response to lipopolysaccharideIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of interleukin-10 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of interleukin-12 productionIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
multicellular organismal response to stressIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
kynurenic acid biosynthetic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
swimming behaviorIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell proliferationIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
negative regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
positive regulation of T cell apoptotic processIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
'de novo' NAD biosynthetic process from tryptophanIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
electron transfer activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
heme bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
indoleamine 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
metal ion bindingIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
tryptophan 2,3-dioxygenase activityIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
smooth muscle contractile fiberIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
stereocilium bundleIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
cytoplasmIndoleamine 2,3-dioxygenase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1276958Inhibition of recombinant human IDO1 assessed as reduction in kynurenine production using L-tryptophan as substrate after 60 mins by microplate reader method2016European journal of medicinal chemistry, Jan-27, Volume: 108O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.
AID1266390Inhibition of human IDO using L-tryptophan as substrate preincubated for 5 mins followed by substrate addition measured after 15 mins by spectrophotometric analysis2015Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
AID362046Induction of Escherichia coli DH5alpha pBSK-2 DNA cleavage in CHES buffer at pH 9.0 after 16 hrs by agarose gel electrophoresis2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Metal-free artificial nucleases based on simple oxime and hydroxylamine scaffolds.
AID362042Inhibition of Escherichia coli DH5alpha pBSK-2 DNA cleavage in HEPES buffer at pH 8.0 after 8 hrs by agarose gel electrophoresis in presence of distamycin2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Metal-free artificial nucleases based on simple oxime and hydroxylamine scaffolds.
AID362043Inhibition of Escherichia coli DH5alpha pBSK-2 DNA cleavage in HEPES buffer at pH 8.0 after 8 hrs by agarose gel electrophoresis in presence of DMSO2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Metal-free artificial nucleases based on simple oxime and hydroxylamine scaffolds.
AID362047Ratio of Kcat to Km for induction of Escherichia coli DH5alpha pBSK-2 DNA cleavage in CHES buffer at pH 9.0 after 16 hrs by agarose gel electrophoresis2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Metal-free artificial nucleases based on simple oxime and hydroxylamine scaffolds.
AID362044Inhibition of Escherichia coli DH5alpha pBSK-2 DNA cleavage in CHES buffer at pH 9.0 after 8 hrs by agarose gel electrophoresis in presence of glycerol2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
Metal-free artificial nucleases based on simple oxime and hydroxylamine scaffolds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (29.03)18.7374
1990's2 (6.45)18.2507
2000's5 (16.13)29.6817
2010's10 (32.26)24.3611
2020's5 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.06 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]